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Abstract
Renal cell carcinoma (RCC) is the major cause of death among patients with von Hippel-Lindau (VHL) disease.
Resistance to therapies targeting tumor angiogenesis opens the question about the underlying mechanisms.
Previously we have described that RWDD3 or RSUME (RWD domain-containing protein SUMO Enhancer) sumoylates
and binds VHL protein and negatively regulates HIF degradation, leading to xenograft RCC tumor growth in mice. In
this study, we performed a bioinformatics analysis in a ccRCC dataset showing an association of RSUME levels with VHL
mutations and tumor progression, and we demonstrate the molecular mechanism by which RSUME regulates the
pathologic angiogenic phenotype of VHL missense mutations. We report that VHL mutants fail to downregulate
RSUME protein levels accounting for the increased RSUME expression found in RCC tumors. Furthermore, we prove
that targeting RSUME in RCC cell line clones carrying missense VHL mutants results in decreased early tumor
angiogenesis. The mechanism we describe is that RSUME sumoylates VHL mutants and beyond its sumoylation
capacity, interacts with Type 2 VHL mutants, reduces HIF-2α-VHL mutants binding, and negatively regulates the
assembly of the Type 2 VHL, Elongins and Cullins (ECV) complex. Altogether these results show RSUME involvement
in VHL mutants deregulation that leads to the angiogenic phenotype of RCC tumors.
Introduction
von Hippel-Lindau (VHL) disease is an autosomal
dominant disorder with a predisposition to highly vas-
cularized tumors development. The most common VHL
manifestations are hemangioblastomas of the central
nervous system and retina, clear cell renal cell carcinoma
(ccRCC), and pheochromocytomas1. It is caused by
mutations in the tumor suppressor gene VHL1–3. VHL
protein is the substrate recognition component of the E3
ligase complex, composed of Cullin-2, Rbx1, Elongin B,
Elongin C, and pVHL, that participates in the oxygen-
sensing system that drives Hypoxia inducible factors alpha
(HIF) degradation4. When VHL gene is mutated and its
function is modified or lost, HIF-1/2-α subunits are sta-
bilized and HIF target genes become activated5,6. HIF
activity is linked to tumor angiogenesis, invasion, cancer
metabolic reprogramming, and metastasis5,7. Although
HIF-1α and HIF-2α have been associated with poor
prognosis in many human cancers5, in some tumors only
one HIF-α subunit is correlated with prognosis. More-
over, in some tumor models the expression of HIF-1-α or
2-α subunits can lead to a divergent outcome8, probably
caused by differential recruitment of coactivators or cor-
epressors to HIF-targeted gene promoters and activation
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of non-overlapping transcriptional programs4,5,8. In
RCCs, which are the leading cause of mortality among
VHL patients6, cumulative evidence support the role of
HIF-2 as the driving force for tumor progression9. In this
regard, there is increasing number of therapies for RCCs
that suppress angiogenesis through targeting HIF-VEGF
signaling9,10. Nonetheless, the resistance to this therapy
remains a major issue9 and opens the question on the
existence of other factors participating in this process11.
Germline VHL missense mutations account for 52% of
all VHL-associated mutations and are the most frequent
kind found in Type 2 form of this disease1,2. The proteins
translated from some of missense mutated VHL gene
retain the functional ability to downregulate HIF12,13,
suggesting additional mechanisms underlying VHL
mutation impact on tumorigenesis14,15. Under this land-
scape, research is focusing in new pathways that might
play a role in HIF-VHL deregulation, in order to get new
knowledge about the molecular mechanism of VHL dis-
ease development16.
Originally isolated from highly tumorigenic and angio-
genic cells, the product of the RWDD3 gene, RSUME
(RWD domain-containing protein SUMO Enhancer) or
RWDD3, increases protein sumoylation17, a dynamic
ubiquitin-like (Ubl) post translational modification18,19. It
has been demonstrated that ubiquitin and Ubl pathways
regulate diverse cellular processes18–20 and its alterations
have been implicated in the pathogenesis of cancer20.
RSUME expression has been reported in organs prone to
develop VHL syndrome tumors17,21. RSUME is upregu-
lated by cellular stress such as hypoxia (HPX)17 and acts
as a negative regulator of VHL function in normoxia
(NMX) promoting HIF-α stabilization17,21. Survival ana-
lysis available at The Human Protein Atlas with a recent
dataset of Cancer Genome Atlas Research Network
(TCGA), shows that 20.07% of the 528 RCC tumors
samples studied express elevated levels of RSUME, that
correlate with a 23% decrease of patients survival rate
(https://www.proteinatlas.org/ENSG00000122481-
RWDD3/pathology/tissue/renal+cancer/KIRC).
To gain insight into the mechanisms of the loss of
function of Type 2 VHL mutants, we investigated the
action of RSUME in the deregulation of HIF-2 by Type 2
VHL mutants. We show that RSUME acts on missense
VHL mutants promoting HIF-2α stabilization. RSUME, in
a sumoylation independent manner, displaces HIF-2-
Type 2 VHL mutants interaction and regulates the loss of
function of VHL mutants on HIF-2α regulation, leading
to enhanced VEGF action and, thus promoting higher
vascularized tumors. RSUME levels are higher in tumor
patients with VHL mutations and associated with poor
prognosis in RCC tumors. Altogether these results sup-
port a key role for RSUME on the early angiogenesis
needed for tumor establishment by Type 2 VHL mutants.
Materials and methods
Materials
Unless otherwise stated, reagents were obtained from
Thermo Fisher Scientific (Waltham, MA, USA) or Sigma
Aldrich (Saint Luis, MO, USA).
Cell culture
COS-7 cells were obtained from ATCC. RCC 786-O
cells, defective in VHL expression3, were obtained from R.
Voest (University Medical Center Utrecht) and EA.hy926
cells (human umbilical vein cell line) from G. Owen
(Pontifical Catholic University of Chile)22. Cells were
cultured as described21,22 in Dulbecco’s modified Eagle’s
medium (DMEM) (pH 7.3) supplemented with 10% fetal
bovine serum (FBS), 2.2 g/l NaHCO3, 10 mM HEPES,
4mM L-glutamine, 100 U/ml penicillin, and 100mg/ml
streptomycin. All cells were cultured at 37 °C, 5% CO2.
Cells were regularly tested for Mycoplasma.
For hypoxia17,21, cells were incubated in DMEM 2% FBS
at 1% O2, 5% CO2, 94% N2 using a hypoxic chamber
ProOx Model 110 (BioSpherix, Parish, NY, USA). For
MG-132 treatment21, cells were incubated in DMEM 2%
FBS with 5 μM MG-132 for 6 h.
Plasmids and transfections
The following plasmids were kindly provided and
described as follows pCEFL, O. Coso; Flag-pcDNA3 and
Flag-VHL, S. Lee; HA-HIF-2α, W. Kaelin; pBI-GLV4R
HRE-LUC, E. Van Meir; V5-Ubc-9 and 6xHis-SUMO-2, R.
Hay; siRSUME and siScramble;17 shRSUME and
shScramble (#KH14185N, SABiosciences, Hilden, Ger-
many);21 V5-RSUME, V5-RSUMEY61A/P62A were
described previously17. Flag-VHLY112H, Flag-VHLR167Q,
Flag-VHLL188V, and Flag-VHLK171R mutants were gener-
ated with directed mutagenesis PCR standard protocol and
cloned in frame into Flag-VHL plasmids with NotI and
HindIII restriction enzymes. After confirming VHL muta-
tions by DNA sequencing, Flag-VHLY112H, Flag-VHLR167Q,
Flag-VHLL188V, primers containing missense mutation
were used in a PCR to generate Flag-VHLY112H/K171R, Flag-
VHLR167Q/K171R, and Flag-VHLL188V/K171R plasmids.
Flag-VHLK171R/shScramble, Flag-VHLK171R/shRSUME,
Flag-VHLL188V/K171R/shScramble, and VHLL188V/K171R/
shRSUME were obtained as described previously21. Cor-
rect sequence was confirmed for all generated plasmids.
Transfections with lipofectamine reagent were per-
formed following the manufacturer indications, as pre-
viously described17.
Stable clones were obtained as described21, RCC 786-O




were selected with Geneticin (G418) at a concentration of
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600 ng/ml. After selection, cells were cultured in DMEM
medium containing 300 ng/ml Geneticin. Mutated VHL and
RSUME expression levels were checked by western blot
(WB) and RT-PCR, respectively.
Western blot assay
WB analysis was performed as described previously17.
Cells lysates were prepared in 2x Laemmly buffer and
separated in sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE). Membranes were incubated
with specific primary antibodies, followed by incubation
with HRP-conjugated secondary antibodies (Bio-Rad
Laboratories, Hercules, CA, USA). Developing was
performed with the SuperSignal West Dura kit according
to manufacturer’s instruction (Pierce Biotechnology,
Waltham, MA, USA) using G:BOX-CHEMI-XT4
(Synoptics Ltd., Cambridge, United Kingdom). The fol-
lowing antibodies were used as already described:17 anti-
V5 (1:3000; Abcam, Cambridge, United Kingdom); anti-
β-actin (C4) (1:2000; Santa Cruz Biotechnologies, Dallas,
TX, USA), anti-Flag (M2) (1:5000); anti-HA (C11)
(1:2000; Covance, Princeton, NJ, USA), anti-HIF-2α
(1:1000; Novus Biologicals, Littleton, CO, USA); anti-
RWDD3 (1:1000; Abcam).
Luciferase assay
Cells were transfected with HRE-LUC and RSV-β-gal,
coding for the bacterial β-galactosidase gene under the
control of the viral RSV promoter, to standardize the results.
After 24 h, cells were washed with Phosphate Buffered Sal-
ine (PBS) and lysed with Passive Lysis Buffer (Promega,
Madison, WI, USA). Luciferase activity was measured using
the Luciferase detection kit (Promega) with a Junior
Luminometer (Berlthod, Bad Wildbad, Germany), as pre-
viously described17.
For β-galactosidase activity, 100 μl of β-galactosidase
buffer (100 mM Na2HPO4/NaH2PO4 pH 7.4, 1 mM
MgCl2, 50 mM β-mercaptoethanol and 0.66 mg/ml 2-
Nitrophenyl β-D-galactopyranoside (ONPG)) were added
to 20 μl of lysates. After incubation at 37 °C, β-
galactosidase activity was determined using iMarkTM
Microplate Reader (Bio-Rad) at 415 nm.
Co-immunoprecipitation
COS-7 cells were co-transfected with indicated
expression vectors. When indicated, cells were treated
with 5 µM MG-132 for 6 h, washed twice with ice cold
PBS, lysed on ice with modified RIPA buffer (50mM Tris-
Hcl pH 7.4, 1 mM EGTA, 1% NP-40, 150mM NaCl),
supplemented with 2 mM Sodium Orthovanadate, 1 mM
PMSF, and protease inhibitors cocktail (Roche, Basilea,
Switzerland). Extracts were immunoprecipitated with the
indicated antibodies as previously described17. Cell lysates
were centrifuged at 12,000 × g for 30 min at 4 °C.
Supernatants were pre-cleared in RIPA buffer with 15 μl
of protein A-agarose beads, followed by immunoprecipi-
tation with indicated antibodies. Twenty-five microliters
of protein A-agarose beads were added to cells extracts
and incubated for 1.5 h at 4 °C. Beads were collected by
centrifugation, washed four times with 500 μl modified
RIPA buffer and boiled at 95 °C for 5 min in 2x Laemmly
buffer.
Tandem immunoprecipitation
Cells were washed with PBS, lysed on ice with modified
RIPA buffer, and tandem immunoprecipitation was per-
formed as previously described21. Cells were washed with
PBS, lysed on ice with modified RIPA buffer, and immu-
noprecipitated with anti-FLAG antibody as described
above. Immunoprecipitates were eluted with 3xFLAG
peptide 100 μg/ml, in 100 µl of RIPA Buffer, for 1 h at
4 °C. After centrifugation, eluates were subjected to
second immunoprecipitation protocol (Tandem immu-
noprecipitation) using anti-V5 antibody (Abcam). WB
analyses were performed with the indicated antibodies.
6xHis-SUMO-2 conjugates purification
6xHis-SUMO-2 conjugates purification was per-
formed as described21. COS-7 cells were transfected
with indicated plasmids. After 48 h, cells were lysed in
6 M guanidine-HCl, 100 mM Na2HPO4/NaH2PO4,
10 mM Tris/HCl, 10 mM iodoacetamide, 5 mM imida-
zole, pH 8. 50 µl of Ni-NTA agarose beads were added
and after incubation for 4 h at room temperature, beads
were sequentially washed with buffer A (8M urea,
100 mM Na2HPO4/NaH2PO4, 10 mM Tris/HCl, 10 mM
iodoacetamide, 5 mM imidazole, pH 8), buffer B (8 M
urea, 100 mM Na2HPO4/NaH2PO4, 10 mM Tris-HCl,
0.2% triton X-100, 10 mM iodoacetamide, 5 mM imi-
dazole, pH 6.3), and buffer C (8 M urea, 100 mM
Na2HPO4/NaH2PO4, 10 mM Tris-HCl, 0.1% triton X-
100, 10 mM iodoacetamide, 5 mM imidazole, pH 6.3).
Elution was performed with 150 mM Tris/HCl pH 6.7,
5% SDS, 200 mM imidazole, 30% glycerol, and 720 nM
β-mercaptoethanol, for 20 min at room temperature.
After centrifugation, supernatants were directly ana-
lyzed by SDS-PAGE and WB.
Quantitative reverse transcription PCR (qRT-PCR)
Quantitative real-time RT-PCR was performed with
cDNA samples from RCC 786-O stable clones. The
amplification reactions of 40 cycles were carried out with
specific primers for VEGF (upper: 5´ AGCTACTGCCA
TCCAATCGA 3´ lower: 5´ GGTGAGGTTTGATCCG
CATA 3´), and RPL19 (upper: 5′ CAATGCCAACTCCC
GTCAGCAGATC 3′; lower: 5′ GTGTTTTTCCGGCA
TCGAGCCC 3´). SYBR Green qPCR amplifications were
performed by Real-time PCR, and the data were analyzed
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with Bio-Rad CFX Manager software. For each sample,
the values were normalized to RPL19 levels.
Conditioned media from clones
RCC 786-O-derived clones were seeded at 1 × 105 cells/
well and maintained under normal culture conditions.
After 24 h cells were maintained in DMEM 2% charcoal
FBS for 72 h. Conditioned medium was collected, cen-
trifuged at 500 × g for 5 min and supernatants were stored
at −80 °C until use.
Tube formation assay
The angiogenic response to conditioned medium was
assessed using an in vitro capillary/tube-like structure for-
mation assay22. Ninety-six-well cell culture plates were
coated with growth factor-depleted Matrigel (Corning inc.,
Corning, NY, USA) for 30min at 37 °C. EA.hy.926 cells
were resuspended in RCC 786-O-derived clones condi-
tioned medium and seeded (1.5 × 104 cells/well) onto 96-
well cell culture plates coated with Matrigel. For negative
control EA.hy.926 cells were resuspended in DMEM 2%
fetal bovine charcoal serum. After 18 h of incubation at
37 °C and 5% CO2, the capillary/tube-like structures were
visualized by light microscopy and were analyzed using NIH
ImageJ software. Two independent experiments were per-
formed. For each conditioned media three individual wells
were photographed and the tube network was quantitated
and expressed as average of tubules from the 6 wells.
In vivo angiogenesis assay
In all, 106 cells of each RCC 786-O clone were harvested
in 90 µl of DMEM and 10 µl of Tripan Blue were added.
Cells were intradermally injected (27 G needle) in the
right flank of 6–8-weeks male NOD/SCID mice (106 cell/
mouse) and vehicle in the left flank. Animals were housed
with access to food and water ad libitum in ventilated
mouse cages (1–5 mice per cage) at the Institute Animal
Services Facility. All animal experimental protocols were
approved by the Ethical Committee on Animal Care and
Use (CICUAL), University of Buenos Aires, Argentina and
performed in compliance with ARRIVE Animal Research
guidelines recommendations. Mice for each group
(treatment) were selected at random. After 7 days, ani-
mals were sacrificed and the skin was removed. Photo-
graphs were taken under magnification glass using ZEN
software (Carl ZEISS, Oberkochen, Germany). Small and
medium vessels were measured using ImageJ software and
vessel density was calculated as (number of vesselscells side
− number of vesselsvehicle side)/Area. Trial experiments
and experiments done previously were used to determine
sample size with adequate statistical power.
For both angiogenesis and tube formation assays data
analysis of Fig. 5b–i were performed by two independent
blinded observers.
RCC tumor samples
The clear renal cell carcinoma (RCC) paraffin samples
were provided by Hospital Italiano de Buenos Aires (VHL
Clinical Care Center of VHL Alliance, USA). This study
complies with the June 1964 Declaration of Helsinki and
has been approved by the Hospital Italiano ethics
committee.
Informed consent was obtained for all patients as part of
the Cancer Genome Atlas consortia. All data used in this
study were downloaded from public websites after the
data were consented for public use.
Immunohistochemistry
Paraffin embedded samples were cut in slides (5 μm).
Deparaffinization and citric acid based antigen retrieval
was performed following standard protocols. Tumor tis-
sues were fixed in 4% paraformaldehyde for 5 min and
blocked in 5% goat serum with 0.1% (v/v) triton X-100 for
1 h at room temperature. Slides were incubated with
RSUME antibody (1:200; Abcam) overnight at 4 °C. After
washing, biotinylated anti-rabbit secondary antibody
(1:300; Vector Laboratories Ltd., Peterborough, United
Kingdom) was added for 30 min at room temperature.
The slides were incubated for 30min with the
avidin–biotin–peroxidase complex (Vector Laboratories
Ltd.). Color development was performed using 1mg/ml
diaminobenzidine with 0.01% hydrogen peroxide for 8 s.
Sections were counterstained with Hematoxiline. Images
were acquired at a magnification x20 in a LSM 710
AxioObserver (Carl ZEISS) microscope.
Bioinformatics analysis
Data
The bioespecimen data of somatic variants identified
from exome sequencing studies of ccRCC tumors corre-
spond to the TCGA Kidney Renal Clear Cell Carcinoma
(Project ID: TCGA-KIRC) of the TCGA Resource Net-
work23. The datasets analyzed during the current study
are available in the NIH, National Cancer Institute, GDC
Data Portal repository, [https://portal.gdc.cancer.gov/
projects/TCGA-KIRC]. The VHL mutational analysis
from tumors with sequencing data was available and
downloaded from Table S1 from Ricketts et al.24.
RSUME expression and tumor stage of the ccRCC tumors
was obtained and downloaded from The human protein
Atlas (https://www.proteinatlas.org/ENSG00000122481-
RWDD3/pathology/tissue/renal+ cancer/KIRC). Expres-
sion data is reported as median FPKM (number Fragments
Per Kilobase of exon per Million reads). In order to main-
tain data consistency, from the complete TCGA Resource
Network dataset we only used those 463 patients samples
and genes that were present in both The Human Protein
Atlas and the Table S1 from Ricketts et al. from the TCGA-
KIRC.
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Survival
The survival Kaplan–Meier analysis for 5-year survival
was conducted by The Human Protein Atlas (https://www.
proteinatlas.org/ENSG00000122481-RWDD3/pathology/
tissue/renal+ cancer) from 528 ccRCC patients (KIRC
dataset).
RSUME expression in ccRCC tumor samples
RCC samples were stratified in two groups according to
the presence of VHL mutation (See Additional file 8:
Table S1). VHL mutated samples were then stratified in
sub-groups according to tumor stage. Total samples for
tumor stage IV were further divided according to VHL
type of mutation. Sample groups were filtered by
removing those samples considered as RSUME expression
outliers. The interquartile range (IQR) was used to find
outliers defined as expression values that fall below first
quartile-1.5 IQR or above third quartile+ 1.5 IQR.
Statistics
As indicated for each experiment ANOVA in a com-
bination with the Scheffé's test, Kruskal–Wallis followed
by a Dunn’s test, Student’s t-test, or Mann–Whitney U-
test were performed as statistics assays. Data are shown as
mean ± SEM. P-values are indicated within each figure.
Data analysis from TGCA dataset was performed using
Python 3.6.1. Significance differences of distributions
between multiple groups were detected through the one-
way ANOVA method. ANOVA assumptions of normality
and homoscedasticity of each sample group were eval-
uated. When any of the assumptions were not satisfied,
log transformation has been applied to the dependent
variable (RSUME expression in FPKM). ANOVA followed
by a post hoc Tukey test was performed in order to assay
RSUME expression values comparisons between means of
tumor stage groups. P‐value of pairwise comparisons
between two sample groups’ distributions of RSUME
expression values were analyzed by non-parametric
Mann–Whitney U-test.
Results
Expression of RSUME is associated with VHL mutations in
RCC tumors
We first studied RSUME expression in tumor samples
by immunohistochemical (IHC) staining and performed a
bioinformatics analysis of RSUME expression in a ccRCC-
TCGA dataset. Figure 1a shows representative staining of
RSUME expression in tumor samples of ccRCC patients,
that is not uniformly expressed. Kaplan–Meier survival
analysis shows that patients exhibiting high RSUME
expression within this cohort had significantly worse
overall survival compared to those with low RSUME gene
expression (Fig. 1b). We next interrogated the TCGA
dataset to assess RSUME gene expression levels
comparing between patients with VHL mutations
(VHLmut) and those without VHL mutations (VHLwt)
and observed significant augmented RSUME levels in
those with VHLmut (P= 0.048; Fig. 1c). To assess the
impact of RSUME expression in RCC progression, we
evaluated the association between RSUME expression
levels and tumor stage distribution in VHLmut samples.
RSUME expression levels were significantly different,
showing a higher level in stage IV than the stages I–II and
III (P= 0.036 and 0.021; Fig. 1d). Given this increase we
next analyzed in more detail the levels of RSUME in stage
IV. Patients with VHL mutations show higher RSUME
levels compared to those without VHL mutations (P=
0.012; Fig. 1e). When we interrogated the datasets for the
levels of RSUME in patients within this group carrying
missense VHL mutations, they also displayed a significant
difference with respect to patients without VHL muta-
tions (P= 0.027; Fig. 1f). Altogether these results indicate
an association of RSUME levels with VHL mutations and
tumor progression.
RSUME potentiates VHL Type 2 loss of function
To understand the basis for the augmented RSUME
levels in patients with VHL mutations (Fig. 1c) we
investigated the regulation of RSUME by VHL mutants in
a RCC cell line. VHL type 2 representative mutants
(Tyr112His, Arg167Gln, and Leu188Val) contrasting to
VHLWT, do not reduce RSUME expression (Fig. 2a),
generating a permissive cellular context for elevated
RSUME levels.
RSUME overexpression in the presence of VHL Type 2
mutants causes increased stabilization of HIF-2α (Fig. 2b).
In cells previously cultured under HPX and next exposed
to NMX, RSUME blocks HIF-2α degradation produced by
the incomplete action of VHL mutants (Fig. 2c–e) or by
VHL (Supplementary Fig. S1). To verify that HIF-α sta-
bilization due to RSUME action on VHL type 2 mutants
produces an increase in HIF transcriptional activity, COS-
7 cells were transfected with HIF transcriptional activity
reporter (HRE-LUC) in combination with the different
variants of VHL. VHL mutants showed decreased but not
completely abolished function, as already reported12,13,
and RSUME significantly increased HIF activity (Fig. 2f),
promoting VHL mutants loss of function.
VHL mutants are sumoylated but RSUME acts
independently of their sumoylation status
To get knowledge about the mechanism involved, we
first evaluated Type 2 VHL mutants sumoylation capacity,
as well as RSUME contribution to it. By affinity purifica-
tion of sumoylated proteins from transiently transfected
cells expressing His-SUMO-2, Ubc-9 and the different
Type 2 VHL mutants, we observed that VHL mutants
are sumoylation substrates (Fig. 3a). Knock-down of
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endogenous RSUME expression with a small-interfering
RNA (siRNA), produced a significant decrease of
sumoylation of transiently expressed variants of VHL
(Fig. 3b). Thus, RSUME acts on VHL disease repre-
sentative mutants as a positive modulator of their
sumoylation.
We next studied if RSUME needs to promote VHL
mutants sumoylation to exert its action. RSUME
increased HIF-2α stability both when VHL WT or
VHLK171R (VHL defective in sumoylation)
25 were
expressed (Supplementary Fig. S2A, B, C), as well as in
cells in which overall sumoylation was inhibited by the
Fig. 1 (See legend on next page.)
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expression of the viral protein Gam-1 (Supplementary
Fig. S2D), indicating that its action as sumoylation
enhancer on VHL is not involved in this mechanism.
RSUME sumo-independent inhibition on VHL is
accompanied by an increase of HIF transcriptional
activity (Fig. 3c).
Given that the consensus site for sumoylation and the
Type 2 mutations are near and in order to confirm that
RSUME retains its action on VHL mutants when their
sumoylation is affected, we generated plasmids expressing
both VHL disease variants and the K171R mutation (VHL
Y112H/K171R, VHLR167Q/K171R and VHLL188V/K171R), which
showed impaired sumoylation (Supplementary Fig. S3).
VHL mutants interact with RSUME (Fig. 3d) and this
interaction is not affected by the VHL sumoylation
mutation (VHLK171R) as double VHL mutants also inter-
act with RSUME (Fig. 3e). In line with this, in RCC 786-O
cells transfected with each single mutant or its corre-
sponding sumoylation defective variant VHLY112H and
VHLY112H/K171R (Fig. 3f), VHLR167Q and VHLR167Q/K171R
(Fig. 3g) and VHLL188V and VHLL188V/K171R (Fig. 3h),
RSUME overexpression stabilized HIF-2α, potentiating
simple and double mutants loss of function (Fig. 3f–h).
RSUME action was also confirmed in transfected COS-7
cells (Supplementary Fig. S4A, B, C). In line with a
sumoylation independent mechanism both VHL and
Fig. 2 RSUME potentiates VHL type 2 mutants loss of function. a RCC-786-O and b–f COS-7 cells were transfected with the following vectors
as indicated in each panel: 0.5 µg of Flag-VHL variants, 0.5 µg of V5-RSUME, 0.1 µg of HA-HIF-2α, 0.7 µg HRE-LUC reporter vector, 0.5 µg RSV-β-
galactosidase or the corresponding empty vectors. a, b Forty-eight hours post transfection cells were lysed or c–e 48 h post transfection cells were
incubated for 4 h in hypoxia (HPX) and then harvested in normoxia (NMX) at the indicated times. Cells extracts were analyzed by WB using the
indicated antibodies. β-actin was used as a loading control. One representative experiment from three experiments with similar results is shown.
f Twenty-four hours post transfection Firefly luciferase (LUC) was measured. Each value was normalized by RSV-β-galactosidase activity. Results are
expressed as mean ± SEM of triplicates of one representative experiment of three experiments with similar results. *P < 0.05 compared with cells
transfected with VHL empty vector (bar 1). **P < 0.01 compared each VHL variant with the corresponding cells transfected with RSUME empty vector.
#P < 0.05 compared with cells transfected with VHL (bar 3) (one-way ANOVA followed by Scheffé’s test)
(see figure on previous page)
Fig. 1 Increased RSUME expression is correlated with VHL missense mutations and poor survival in RCC patients. a Representative
immunohistochemistry (IHC) staining for RSUME in three ccRCC patient samples. Scale bars 100 µm and 50 µm as indicated. b Kaplan–Meier analysis
in patients stratified as having high (violet line) RSUME expression or low (blue line) RSUME expression (expression cutoff 2.9 FPKM), publically
available from The Human Protein Atlas. c Box plots comparison between RSUME mRNA expression in a patient stratification of the Additional file 8:
Table S1 data (where VHLwt= 207 samples without mutations in VHL gene, VHLmut= 245 samples with mutations in VHL gene). *Significant
differences between sample groups distribution with a P= 0.048, < 0.05 (Mann–Whitney U-test). d Box plots comparison between RSUME mRNA
expression in a patient stratification of the Additional file 8: Table S1 data with mutations in VHL cohort (VHLmut) into tumor stages (where stage I–II
represent samples corresponding to tumor stages I and II= 150 samples; stage III represents samples corresponding to tumor stage III= 58 samples;
stage IV represents samples corresponding to tumor stage IV= 37 samples). Significant differences between sample group means with a P= 0.036 (*)
and 0.021 (#), < 0.05 (ANOVA and post hoc Tukey tests). e, f Box plots comparison between RSUME mRNA expression in a patient stratification
of the Additional file 8: Table S1 data in stage IV cohort into mutation types (where VHLwt= 34 samples without mutations in VHL gene,
VHLmut= 37 samples with mutations in VHL gene, VHLmiss= 18 samples with mutations missense in VHL gene only). *Significant differences
between sample groups distribution with a P= 0.012 (5e), and 0.027 (5f), < 0.05 (Mann–Whitney U-test)
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VHLK171R co-immunoprecipitated with the RSUMEYAPA
variant, carrying a mutation on a conserved residue of its
RWD-domain essential for sumoylation enhancement
(Supplementary Fig. S5, lanes 6 and 8).
Altogether, these results indicate that VHL mutants are
sumoylated but its sumoylation is not involved in RSUME
potentiation of VHL mutants loss of function.
RSUME acts on VHL Type 2 mutants by decreasing mutant
VHL–HIF binding and by disrupting their ECV complex
assembly
To explore the molecular mechanism by which RSUME
impacts on VHL mutants function, we next addressed
whether RSUME would coexist with VHL variants and
HIF-2α in a complex. We performed tandem immuno-
precipitation (first purification: VHL-associated proteins;
second purification: RSUME-associated proteins), show-
ing that in addition to binding to VHL Type 2 mutants
RSUME participates in a VHL–HIF-RSUME complex for
all Type 2 mutants (Fig. 4a). RSUME decreases the
binding of HIF-2α to all disease VHL mutants analyzed
(Fig. 4b) even when a slight increase of VHL was
observed, providing a molecular basis by which RSUME
potentiates their loss of function. Moreover, when
sumoylation was inhibited by Gam-1 or in presence of
VHL defective for sumoylation, RSUME also impaired
VHL–HIF-2α interaction (Fig. 4c, d), further confirming
that RSUME-mediated decrease in HIF-VHL mutant
binding is the mechanism responsible for HIF stabiliza-
tion. Furthermore, the interaction of RSUME with VHL
type 2 mutants impacts on the ECV complex assembly,
affecting VHL variants binding to Elongin C and Elongin
B (Fig. 4e).
RSUME participates in early angiogenesis produced by
VHL mutants
Next, we studied RSUME contribution to early stages of
VHL tumorigenesis. In particular, we focused on the
angiogenic switch associated to an increase in VEGF, due
to HIF transcriptional activity deregulation. In RCC 786-
O clones expressing VHL, VHLK171R, VHLL188V or
VHLL188V/K171R, co-expression of shRNA against RSUME
resulted in a decrease of VEGF mRNA, indicating that
through the mechanism described above, RSUME impacts
Fig. 3 RSUME acts on VHL mutants in a sumoylation independent manner. a, b COS-7 cells were transfected with the following vectors: 0.6 μg
of each Flag-pVHL variant, 0.6 μg of 6xHis-SUMO-2, 0.1 μg of V5-Ubc-9 expression vectors, 20 μM siRNA against RSUME or Scramble as a control. Forty-
eight hours post transfection cells were harvested, lysed and an aliquot of the lysates was analyzed by WB (Input). The remaining extracts were
subjected to Ni2+ affinity chromatography to purify 6xHis-SUMO-2 (Ni-NTA). Purified fraction and Inputs were analyzed by WB using Flag antibody.
One representative experiment from two independent experiments with similar results is shown. c–e COS-7 cells were transfected with the following
vectors: 0.7 μg of HRE-LUC reporter vector, 0.2 μg of RSV-β-galactosidase control vector and/or 0.5 μg of V5-RSUME and/or 0.5 μg of Flag-pVHL or
Flag-VHLK171R, 0.5 μg of indicated Flag-VHL variants and/or respective empty vector as control. c Twenty-four hours post transfection Firefly luciferase
(LUC) was measured. Each value was normalized by RSV-β-galactosidase activity. Results are expressed as mean ± SEM of triplicates of one
representative experiment of three experiments with similar results. *P < 0.05 and **P < 0.01 compared with cells transfected with the corresponding
RSUME empty vector, #P < 0.05 compared to VHL empty vector without RSUME (one-way ANOVA followed by Scheffé’s test). d, e Forty-eight hours
post transfection cells extracts were Immunoprecipitated with anti-FLAG antibodies. Immunoprecipitated fractions and extract aliquots (Input) were
analyzed by WB using the indicated antibodies. One representative experiment from three independent experiments with similar results is shown.
f–h RCC 786-O cells were transfected with 1.0 μg of Flag-VHL indicated variant and/or 1.5 μg of V5-RSUME expression vectors. Forty-eight hours post
transfection cells were lysed and extracts were analyzed by WB using the indicated antibodies. β-actin was used as a loading control. One
representative experiment from two independent experiments with similar results is shown
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on VHL function (Fig. 5a). Similar results were obtained
for VHLY112H/K171R and VHLR167Q/K171R co-expressing
RSUME shRNA clones (Supplementary Fig. S6).
To determine how these changes in VEGF may con-
tribute to differential tumoral vessel formation, we first
performed in vitro tube formation assays. When EA.
hy926 endothelial cells were cultured in conditioned
media of clones in which RSUME was silenced, there
was a significant decrease in capillary-like structures
formation (Fig. 5b–e and Supplementary Fig. S6). To
study angiogenesis in a more complex context26,
RSUME role on early angiogenic progress associated to
VHL function was further demonstrated in an in vivo
angiogenesis model. After 7 days, mice injected with
stable clones expressing either VHLWT or VHLL188V
presented new vessels around the injection area, but
those clones in which RSUME expression was knocked-
down showed a significant decrease in vessel density
(Fig. 5f and h). This confirms, in vivo, that in absence
of RSUME, VHL Type 2 mutant become more potent
and might limit early tumoral angiogenesis. In accor-
dance with the fact that RSUME impacts on VHL
function independently of its sumoylation status,
RSUME silencing resulted in a gain of function of both
VHLWT and VHLL188V defective sumoylation variants
(Fig. 5g and i).
Discussion
RSUME was found to be expressed in several types of
tumors with high angiogenic potential17,27–30. RSUME is
expressed in tissues prone to tumor development in VHL
syndrome17 and is upregulated in several tumors related
to this disease21. High RSUME expression is associated
with poor prognosis in RCC. Thus, RSUME might be a
potential biomarker of the outcome of the disease. Our
findings support a model in which RSUME is not down-
regulated in presence of VHL mutants, achieving high
RSUME expression in specific tissues, were RSUME
becomes critical for potentiating the missense VHL loss
of function on HIF-2-α degradation, providing a permis-
sive setting for the development of VHL tumors and
promoting deregulated angiogenesis needed for tumor
progression (Fig. 6).
Mutations in VHL generate reduction or absence of its
function, which leads to a marked and unregulated
amplification of HIF activity under non-hypoxic condi-
tions31. There are mutant VHL isoforms that seem to
behave similarly to wild-type VHL in terms of HIFα sta-
bilization12,13 opening the question about the mechanisms
by which these mutations impact on tumor phenotype31.
Other alterations associated with VHL missense muta-
tions, such as loss of PBRM1 or BAP111, or changes in
proteostasis of VHL12, have been proposed to support
Fig. 4 RSUME potentiates VHL mutants loss of function by decreasing VHL–HIF interaction and ECV complex assembly. a–d COS-7 cells
were transfected with 0.5 µg of Flag-VHL variants, 0.5 µg of V5-RSUME, 0.5 µg of HA-HIF-2α, 0.1 μg of Gam-1, Gam-1MUT control vector. a Forty-eight
hours post transfection cells were incubated in 2% serum, 5 μM MG-132 for 6 h and lysed. A first immunoprecipitation (IP) using anti-FLAG antibody
was performed. Immunoprecipitated fractions were eluted with soluble FLAG peptide and a second IP using anti-V5 antibodies was performed.
Immunoprecipitated fractions from the second IP “Tandem IP” and extract aliquots (Input) were analyzed by WB using the indicated antibodies.
b–d Cells extracts were immunoprecipitated with anti-FLAG antibodies. Immunoprecipitated fractions and extract aliquots (Input) were analyzed
by WB using the indicated antibodies. One representative experiment from three independent experiments with similar results is shown. e Cells
were transfected with 0.5 μg of the indicated Flag-VHL-GFP variants, 0.5 μg of Flag-Elongin C, 0.5 μg of HA-Elongin B, 0.5 μg of Cullin-2 and/or 0.5 μg
of V5-RSUME expression vectors. Forty-eight hours post transfection cells were lysed and lysates immunoprecipitated with GFP antibody.
Immunoprecipitated fractions and extract aliquots (Input) were analyzed by WB using the indicated antibodies. One representative experiment
from two independent experiments with similar results is shown
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Fig. 5 (See legend on next page.)
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VHL pathological function. VHL has been identified as a
multiadaptor protein, interacting with 117 different
binding partners32. In this landscape RSUME emerges as a
VHL modulator: it is expressed in VHL syndrome tumors,
interacts with VHL mutants and promotes HIF-2α sta-
bilization by disruption of the VHL interactions.
While VHL mutants are able to degrade HIF-α12,13, in
presence of RSUME their ability to act on HIF-2 degra-
dation worsens, displaying its loss of function. An in
silico analysis of the effect of VHL mutations found
in RCC samples shows that missense loss of function
could be achieved by an impaired interaction between
VHL mutants and interacting proteins33. In connection
with this, several groups have demonstrated altered
VHL-partners interactions34,35. The interaction of VHL
mutants with HIF and RSUME show that RSUME over-
expression disrupts HIF-2α-VHL mutants binding, shed-
ding light onto the underlying mechanism behind HIF-2
stabilization. RSUME also decreases the recruitment of
Elongin B and C to the complex. The reduced but still
partial ability of some VHL mutants to bind to Elongin C
and B has been shown to explain in part their capacity
to still partially degrade HIF13. The protein–protein
interaction of VHL mutants with RSUME impairs the
ECV complex assembly contributing to the establishment
of the mutant pathogenic phenotype.
Post translational modifications like ubiquitination
and hydroxylation have been described as regulators of
the oxygen-sensing system31. Particularly, dynamic
sumoylation of HIF, involving SENP136, has been implied
in the regulation of HIF stabilization17,36. In addition to
this, sumoylation of other components of the HIF system
such as hypoxia associated factor (HAF) has been con-
nected with the reprograming of HIF-2 response during
VHL loss, needed for RCC tumor progression37. Sumoy-
lation of VHL is relevant to affect its function as tumor
suppressor25,38. Sumoylation/ubiquitination on Lysines
171 and 196 actively regulate VHL spatial distribution and
decrease HIF-α inhibition38. We found that missense
VHL proteins are sumoylated in presence of RSUME.
In this context we tested if RSUME operates for its action
on the loss of function of the mutants, through its
sumoylation activity. Using a VHL sumoylation-deficient,
which is mutated in Lysine 171, we observed that RSUME
diminishes the binding between HIF and Type 2 VHL
mutants defective in sumoylation and increases HIF-2α
stability and transcriptional response, proving that this
action of RSUME is mediated by a VHL sumoylation
independent mechanism.
As already indicated 20.07% of 528 RCC samples
showed high RSUME levels and a 23% decrease in survival
rate. RSUME expression levels are higher in patients with
VHL mutations, particularly in those in stage IV of the
(see figure on previous page)
Fig. 5 RSUME impacts on VHL mutants function and increases early angiogenesis. a RCC 786-O clones were lysed and VEGF mRNA levels were
analyzed by quantitative real-time RT-PCR in triplicates. Values are given as mean ± SEM after normalization to RPL19. *P < 0.05 and **P < 0.01
compared with the corresponding shScramble clone (one-way ANOVA followed by Scheffè’s test). b, c The conditioned medium from RCC 786-O
clones was tested for tube formation assay in vitro. In all, 15,000 Eahy.926 cells/well were incubated with 100 µl of conditioned media. Photographs
were taken 18 h post incubation using an inverted microscope (magnification: 5 × ). Scale bar 400 µm. One representative picture for each clone
of two independent experiments is shown. d, e Quantification of number of capillary/tube-like structures in b and c. Values are mean from two
experiment ± SEM. Three independents wells were analyzed per experiment. P-value was determined by Kruskal–Wallis followed by a Dunn’s test.
*P < 0.05 and **= P < 0.01 compared with the corresponding shScramble clone. f, g RCC 786-O clones (106 cells, each clone) were intradermal
injected in the right flank of 6–8-weeks male NOD/SCID mice. Vehicle was injected in the left flank (contralateral flank). After 7 days, the skin was
removed and photographs were taken under magnification glass. Pictures representative of each condition with similar results to the others of each
group are shown. Scale bar 5 mm. h, i Quantification of vessel density calculated (number of vesselscells side – number of vesselsvehicle side)/Area.
Results obtained from two independent experiments with four independent pictures for each condition are expressed as mean ± SEM. *P < 0.05 and
**P < 0.01 compared with the corresponding Scramble clone (Kruskal–Wallis followed by a Dunn’s test)
Fig. 6 Proposed model for RSUME increase in VHL tumors and its
action on VHL mutants function. VHL missense Type 2 mutants fail
in negatively regulate RSUME levels, leading to a permissive context
for increased RSUME in VHL-related tumors, like RCC. By
protein–protein interaction with VHL mutants, RSUME reduces HIF-2α-
VHL binding and negatively regulates the assembly of the ECV
complex. By this mean, RSUME regulates VHL Type 2 mutants loss of
function and worsens HIF transcriptional activity deregulation, thus
leading to increased angiogenesis and tumor progression
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disease. Among those mutations, patients with missense
VHL mutations showed increased RSUME levels. Both
the lack of negative feedback compared to that exerted
by normal VHL and the upregulation mediated by
tumor hypoxia explain these higher levels of RSUME.
The mutations create a permissive context for RSUME
increased levels that regulate their loss of function and
worsens the rate of survival of the patients. RSUME is
not uniformly expressed in RCC tumors, in accordance
with the intratumoral heterogeneity observed in RCC
tumor samples39–41. Future pathological studies will be
necessary to determine the relevance of its location.
One of the most relevant transcriptional targets of the
HIF pathway in the tumoral context is VEGF.
Mutations in VHL that impact on its function generate
a permissive setting for deregulation of VEGF31. As
overproduction of VEGF promotes deregulated blood
vessel formation42 and thus, high-vascularized
tumors43,44, inhibitors that target VEGF and VEGF
receptors (VEGFRs) have been used in the clinic10. Lately,
therapies were also combined with novel HIF-2 activity
inhibitors6,9. Resistance to these targeted therapies point
to the need in understanding the molecular aspects that
are involved in VHL disease setting. New approaches aim
to impact on other crucial mediators45,46, which act on
other signaling pathways that may provide escape routes
that limit currently established treatments47,48. One
strategy would be to act upstream HIF stability regulation,
since HIF deregulation has been associated to the
imbalance of factors that induce a proangiogenic scenario,
thus triggering the tumoral angiogenic switch49,50. In
line with this, a report in Hepatocellular Carcinoma
tumor model showed decreased HIF-1 and 2α, VEGF
and angiogenesis when wild-type VHL is upregulated47.
RSUME binds missense VHL mutant proteins in nor-
moxic conditions in which VHL is active and RSUME,
mutant VHL and HIF-2α coexist in the same protein
complex, suggesting that RSUME could act on HIF-2α
deregulation by missense VHL mutants previous to the
tumoral hypoxic state development. Silencing RSUME
resulted in powerful wild-type and mutant VHL activity in
early stages of angiogenesis switch, as shown in the
in vitro tube formation and in in vivo angiogenesis assays.
These results let us to suggest RSUME as a potential
target to switch off angiogenesis in VHL-related tumors.
Taking together, our results reveal a protein–protein
interaction mechanism involved in the VHL Type 2
mutants’ loss of function phenotype through the action of
RSUME, both in vitro and in vivo. Supporting this, the
bioinformatics analysis from TCGA dataset showing that
RSUME increased levels are associated with VHL muta-
tions and poor patients prognosis highlight the key role of
RSUME as a possible biomarker of RCC VHL disease
outcome. These findings hold the potential of adding a
new target to those therapeutic strategies aimed to switch
off angiogenesis in VHL tumors.
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